S
Sander G. Mills
Researcher at Merck & Co.
Publications - 208
Citations - 8715
Sander G. Mills is an academic researcher from Merck & Co.. The author has contributed to research in topics: Chemokine receptor & Tachykinin receptor. The author has an hindex of 50, co-authored 208 publications receiving 8515 citations. Previous affiliations of Sander G. Mills include United States Military Academy.
Papers
More filters
Journal ArticleDOI
Distinct Mechanism for Antidepressant Activity by Blockade of Central Substance P Receptors
Mark S. Kramer,N.R. Cutler,John P. Feighner,Ram K. Shrivastava,John Carman,John J. Sramek,Scott A. Reines,Guanghan Liu,Duane B. Snavely,Edwina Wyatt-Knowles,Jeffrey J. Hale,Sander G. Mills,Malcolm MacCoss,Christopher John Swain,Timothy Harrison,Raymond G. Hill,Franz Hefti,Edward M. Scolnick,Margaret A. Cascieri,Gary G. Chicchi,Sharon Sadowski,Angela Williams,Louise Hewson,David D. Smith,Emma J. Carlson,Richard Hargreaves,Nadia M.J. Rupniak +26 more
TL;DR: The localization of substance P in brain regions that coordinate stress responses and receive convergent monoaminergic innervation suggested that substance P antagonists might have psychotherapeutic properties was found to be correct.
Journal ArticleDOI
Immune Cell Regulation and Cardiovascular Effects of Sphingosine 1-Phosphate Receptor Agonists in Rodents Are Mediated via Distinct Receptor Subtypes
Michael J. Forrest,S.-Y. Sun,Richard Hajdu,James D. Bergstrom,Deborah Card,George A. Doherty,Jeffrey J. Hale,Carol Ann Keohane,C. Meyers,James A. Milligan,Sander G. Mills,N. Nomura,Hugh Rosen,Mark Rosenbach,G.-J. Shei,I. I. Singer,M. Tian,S. West,V. White,Jenny Xie,Richard L. Proia,Suzanne M. Mandala +21 more
TL;DR: Three lines of evidence link S1P3 receptor activity with acute toxicity and cardiovascular regulation: compound potency on S 1P3 correlated with toxicity and bradycardia; the shift in potency of phosphorylated-FTY720 for inducing lymphopenia versus brady Cardia and hypertension was consistent with affinity for S1 p1 relative to S1p3; and toxicity, brady cardia, and hypertension were absent in S1 P3-/- mice.
Patent
Morpholine and thiomorpholine tachykinin receptor antagonists
Conrad P. Dorn,Paul E. Finke,Jeffrey J. Hale,Malcolm MacCoss,Sander G. Mills,Shrenik K. Shah,Mark Stuart Chambers,Timothy Harrison,Tamara Ladduwahetty,Brian John Williams +9 more
TL;DR: Substituted heterocycles of the general structural formula: ##STR1## are tachykinin receptor antagonists useful in the treatment of inflammatory diseases, pain or migraine, asthma and emesis as mentioned in this paper.
Journal ArticleDOI
Structural Optimization Affording 2-(R)-(1-(R)-3,5-Bis(trifluoromethyl)phenylethoxy)-3-(S)-(4-fluoro)phenyl-4- (3-oxo-1,2,4-triazol-5-yl)methylmorpholine, a Potent, Orally Active, Long-Acting Morpholine Acetal Human NK-1 Receptor Antagonist
J. J. Hale,Sander G. Mills,M. Maccoss,P. E. Finke,Margaret A. Cascieri,Sharon Sadowski,E. Ber,Gary G. Chicchi,Myra B. Kurtz,Joe Metzger,George J. Eiermann,Nancy N. Tsou,F.D. Tattersall,Nadia M.J. Rupniak,Angela Williams,W. Rycroft,Richard Hargreaves,D. E. Macintyre +17 more
TL;DR: The activity of 17 at extended time points in these preclinical animal models sets it apart from earlier morpholine antagonists (such as 4), and the piperidine antagonists 2 and 3 and could prove to be an advantage in the treatment of chronic disorders related to the actions of Substance P.
Journal ArticleDOI
Chemistry of tricarbonyl hemiketals and application of Evans technology to the total synthesis of the immunosuppressant (-)-FK-506
TL;DR: In this paper, the chemistry of the tricarbonyl region of FK-506 and its use in designing a sucessful route to this immunosuppressant is outlined.